Form 4: Insmed Director Melvin Sharoky Receives RSU Grant
Statement of Changes in Beneficial Ownership
Insmed Incorporated Director Melvin Sharoky was granted 3,305 restricted stock units as part of his annual director compensation.
Summary
- Director Melvin Sharoky acquired 3,305 Restricted Stock Units (RSUs) on May 13, 2026.
- The RSUs represent a contingent right to receive one share of common stock per unit.
- The grant is subject to vesting conditions, including continued board service until the earlier of the first anniversary or the next annual shareholder meeting, and a 75% board meeting attendance requirement.
- Following this transaction, the reporting person's direct beneficial ownership of common stock increased to 246,081 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents standard director compensation rather than a strategic shift or market-moving financial update.
Positives
- The transaction reflects standard director compensation practices, aligning the interests of the board member with shareholders.
Negatives
- None identified.
Risks
- Vesting of the RSUs is contingent upon meeting specific attendance and service requirements.
Future Outlook
The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director equity compensation.
Industry Context
StockSavvy.ai notes that this filing is a routine disclosure of director equity compensation, which is standard practice for publicly traded biotechnology companies to ensure board alignment with long-term shareholder value.
Comparison to Industry Standards
- The grant of RSUs to non-employee directors is consistent with standard corporate governance practices in the biopharmaceutical sector.
- The vesting conditions, including attendance requirements, are typical for board-level equity incentive plans.
Related Party Transactions
- The reporting person maintains indirect ownership through a spouse, Padonia, LLC, and several UTMA accounts for family members.
Stakeholder Impact
- Minimal impact on shareholders as this is a routine equity grant.
Next Steps
- Vesting of the RSUs on the first anniversary of the grant date, subject to meeting service and attendance criteria.
Key Dates
| Date | Description |
|---|---|
| 05/13/2026 | Date of RSU grant and earliest transaction. |
| 05/15/2026 | Date of filing. |
Keywords
Insmed, INSM, Form 4, Insider Trading, Director Compensation, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.